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Background: Chronic low back pain (LBP) and neck pain (NP) are highly prevalent conditions resulting in high
economic costs. Treatment guidelines recommend relaxation techniques, such as progressive muscle relaxation, as
adjuvant therapies. Self-care interventions could have the potential to reduce costs in the health care system, but
their effectiveness, especially in a usual care setting, is unclear. The aim of these two pragmatic randomized studies
is to evaluate whether an additional app-delivered relaxation is more effective in the reduction of chronic LBP or
NP than usual care alone.
Methods/design: Each pragmatic randomized two-armed study aims to include a total of 220 patients aged 18 to
65 years with chronic (>12 weeks) LBP or NP and an average pain intensity of ≥ 4 on a numeric rating scale (NRS)
in the 7 days before recruitment. The participants will be randomized into an intervention and a usual care group.
The intervention group will be instructed to practice one of these 3 relaxation techniques on at least 5 days/week
for 15 minutes/day over a period of 6 months starting on the day of randomization: autogenic training, mindfulness
meditation, or guided imagery. Instructions and exercises will be provided using a smartphone app, baseline
information will be collected using paper and pencil. Follow-up information (daily, weekly, and after 3 and 6 months)
will be collected using electronic diaries and questionnaires included in the app.
The primary outcome measure will be the mean LBP or NP intensity during the first 3 months of intervention based
on daily pain intensity measurements on a NRS (0 = no pain, 10 = worst possible pain). The secondary outcome
parameters will include the mean pain intensity during the first 6 months after randomization based on daily
measurements, the mean pain intensity measured weekly as the average pain intensity of the previous 7 days
over 3 and 6 months, pain acceptance, ‘LBP- and NP-related’ stress, sick leave days, pain medication intake, adherence,
suspected adverse reaction, and serious adverse events.
Discussion: The designed studies reflect a usual self-care setting and will provide evidence on a pragmatic self-care
intervention that is easy to combine with care provided by medical professionals.
Trial registration: ClinicalTrials.gov identifier Relaxback NCT02019498, Relaxneck NCT02019134 registered on 18
December 2013.
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Low back pain (LBP) and neck pain (NP) are highly
prevalent conditions in industrialized countries with an
estimated lifetime prevalence of 84% [1] and 30 to 70%,
respectively [2,3]. Of 281 conditions investigated in the
Global Disease Study 2010, LBP ranked first and NP
ranked fourth on a measure of years lived with disability
in Western Europe [4,5]. The global point prevalence of
LBP was 9.4% (95% CI 9.0 to 9.8) [6] and that of NP was
4.9% (95% CI 4.6 to 5.3) [7]. In a representative survey
of the German population from 2009, 20.7% of the
respondents reported to have had LBP for at least
3 months in the previous year [8]. Work absence, dis-
ability and medical costs related to LBP and NP generate
a high individual and societal burden [4,9,10]. Individ-
uals suffer from a decrease in their quality of life and
societal ramifications include absenteeism and early re-
tirement [10,11]. In Germany, the annual costs (direct
and indirect) of back pain have been estimated at 16.4 to
50 billion Euro (approximately 2.2% of the gross domes-
tic product in 2006) [12]. Although the majority of
patients experience pain relief within 3 months, approxi-
mately 5 to 20% of individuals with LBP [13] and NP
[14,15] will develop sub-acute and chronic LBP. Numerous
LBP and NP treatments exist, although available evidence
suggests no more than moderate effects from most of the
available treatments [16,17]. Pain experts agree that most
pain is best treated using a combination of medication with
a self-management, complementary, non-drug therapy [18].
Therefore, in the last decade, multimodal treatment strat-
egies have been established by national and international
guidelines combining education, physiotherapy, medication,
self-care and behavioral therapies [17,19-23]. In the
German national guidelines on LBP, paracetamol,
NSAIDs and opioid analgesics (not longer than 3 months)
are recommended as drug therapy. Physical activity, relax-
ation, ergotherapy, manipulation/mobilization, education,
and behavioral therapies are recommended as non-drug
therapies for chronic LBP [19]. Chronic NP should be
treated with physiotherapy, and if necessary, in combin-
ation with manual therapy, post-isometric relaxation and
muscle strengthening, and intramuscular injection of lido-
caine. Other therapies based on patient preferences could
be considered but cannot be recommended based on
strong evidence [17]. The integration of active self-care
therapies, such as ‘mind-body therapies’, for chronic pain
treatment is supported by evidence [24]. Additionally, self-
care interventions are highly attractive because they could
reduce expenses for health care systems, are relatively safe,
and might have health benefits beyond the effects on pain
[24-27]. ‘Mind-body therapies’ including relaxation, medi-
tation and guided imagery are easily applicable as self-care
interventions and are used as adjuvant therapies for the
treatment of chronic pain [28,29]. One aim of severalmind-body therapies, including relaxation techniques and
meditation, is to reduce chronic stress and enhance well-
being through the elicitation of the ‘relaxation response
(RR)’ the opposite of the body’s stress response to per-
ceived threats [30]. The RR is induced when a person
focuses on a word, sound, phrase, repetitive prayer, or
movement, and disregards everyday thought [31]. The re-
laxation response is defined as a physical state character-
ized by decreased arousal of the sympathetic nervous
system [32] and is the opposite of the stress or ‘fight or
flight’ response [30,32]. Progressive muscle relaxation
(PMR) has been shown to be an effective treatment for re-
ducing chronic non-specific NP [33] and in Germany,
PMR is recommended by the national disease manage-
ment guidelines for LBP [19] and by the ‘guideline NP’ of
the German Society of General Practice and Family Medi-
cine [17]. ‘Mindfulness-based’ therapies have been shown
to be effective based on clinical studies on the treatment
of chronic pain [34], and a Cochrane review on patients
with chronic LBP suggested that therapy using PMR or
electromyographic (EMG) biofeedback is more effective
than control treatments for pain relief and improving
short-term functional status; however, this evidence was of
low quality [35]. There has been encouraging evidence
from a systematic review that showed that guided imagery
can reduce musculoskeletal pain [36] and limited evidence
that ‘mindfulness-based’ stress reduction improves pain
acceptance [37]. Autogenic training (AT) is a commonly
used self-help relaxation technique that is easily applicable
in daily life [38]. Most of the mind-body therapies train pa-
tients in a group setting, but alternative delivery methods
such as audio guidance from a smartphone may be more
pragmatic in a usual care setting. Smartphones are increas-
ingly common in the population. In Germany, it was esti-
mated in February 2014 that 40 million people owned a
smartphone [39], which is approximately 49.5% of the Ger-
man population [40]. Coinciding with the popularity and
wide utilization of smartphones, the number of available
smartphone applications (apps) has increased rapidly [41],
and apps are currently used to support people with various
health problems. In a search conducted in July 2012, in the
official Android, BlackBerry and iPhone Smartphone app
platform stores in the United States, 220 pain apps were
identified. Chronic non-specific pain was the focus of more
than half (55.5%) of the apps followed by back pain and/or
NP (25.9%) with the purpose of the apps being pain
education (24.1%), pain self-management (62.3%) and both
education and pain management (13.6%). Health care pro-
fessionals were only involved in the development of a small
number of these apps (35%) [42]. In a further search
conducted between June and August 2010 in the official
stores of the five major operating systems (iOS, Android,
Blackberry OS, Nokia/Symbian and Windows Mobile) for
available apps against pain, headache and migraine were
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pain. The reported purpose of the apps was mostly pain
relief or educational information about pain. Apps that
target pain often include an audio relaxation component.
Regrettably, there is limited available information on the
effectiveness of those apps as self-care interventions [41].
Furthermore, to date, the effectiveness of additional relax-
ation on chronic LBP or NP in a usual care setting is un-
clear. The aim of these two pragmatic randomized studies
is to evaluate whether additional app-based delivered re-
laxation is more effective in the reduction of chronic LBP
or NP than usual care alone.
Methods/Design
Design
Each study is a two-armed, randomized, parallel group,
single center pragmatic trial investigating the effective-
ness of additional relaxation exercise for patients with
chronic LBP (Relaxback) and NP (Relaxneck) compared
to usual care alone. The intervention duration is 6 months,
with the primary outcome summarizing the effect in the
first 3 months.
An app has been developed for collecting outcome
data and to provide the relaxation intervention in the
form of audio content to the participants of the inter-
vention group.
As an essential part of comparative effectiveness re-
search [43], stakeholders were included in the planning
of the study. In July 2013, one stakeholder meeting in-
cluded patients with NP (n = 3) and LBP (n = 4), psycholo-
gists (n = 2) and clinical researchers (n = 2). Stakeholder
involvement resulted in the following resolutions:
 Duration of the intervention was shortened from 20
to 15 minutes daily
 Participants can individually determine the time at
which they will receive their push notifications
 Diary content was determined (questions about the
intensity of the pain, intensity of ‘LBP-/NP-related’
stress, adherence, and amount of pain medication
intake)
 The German translation (Imaginationstraining) of
guided imagery was determined.
Participants
Potential participants will be informed with brochures
and posters at universities, colleges, gyms, and doctors’
offices. The studies will include patients aged 18 to
65 years with chronic LBP or NP (≥12 weeks) and a
mean pain score of ≥ 4 on a numeric rating scale (NRS)
in the previous week. In order to be included in the
studies, the patients have to be willing to be randomized
and provide written and oral informed consent; further-
more, patients are required to follow study interventionsaccording to the protocol, to complete the baseline
questionnaire in paper form as well as electronic ques-
tionnaires and diaries provided by a smartphone appli-
cation. Additionally, having a smartphone (iPhone or
Android) is required. Participants must identify LBP
or NP as their primary complaint to participate in the
Relaxback or Relaxneck study, respectively.
Participants are excluded in case of their LBP/NP be-
ing caused by a known malignant disease, trauma, the
presence of a known rheumatic disorder, a history or
planned surgery of the spinal column of the low back/
neck in the next 6 months, known neurological symp-
toms: for example, radicular symptoms because of a pro-
lapsed disc, regular intake of analgesics (> once per
week) because of additional disease, intake of centrally-
acting analgesics, or a history of severe acute or chronic
disorders that do not allow participation in the therapy.
Further exclusion criteria include known alcohol or
substance abuse, insufficient German language skills,
current application for a pension claim, participation in
another clinical trial during the 6 months before the
study and parallel to the study or applying regular relax-
ation techniques, mindfulness meditation or any other
‘mindfulness-based’ therapy 6 weeks before the study or
planned in the next 6 months.
Randomization
For both studies, if a participant meets all inclusion
and none of the exclusion criteria, they will be ran-
domized to either the control (usual care only) or the
intervention (usual care plus relaxation) group using
blocked randomization with variable block lengths and
an allocation ratio of 1:1, that is 110:110 participants
for each study. The randomization sequence will be
generated by a data manager, who will not be involved
in the analysis of the data or the enrollment of the pa-
tients; SAS (version 9.3, SAS Inc., Cary, NC, USA) will
be used for this process. The randomization list will
be included in a safe Microsoft Access (Redmond,
WA, USA) database to ensure that it is not accessible
during the randomization process of individual partici-
pants and that screened patients are strictly consecutively
enrolled. The randomization process will be conducted
by the study office at the Institute for Social Medicine,
Epidemiology, and Health Economics. To ensure allocation
concealment upon inclusion into the study, the staff will
enter participants into the database and will receive the
intervention or control group allocations.
The app
The app includes relaxation audio files, notification fea-
tures, diaries, and questionnaire options. The app was
developed for smartphones running the iOS or Android
operating systems. The app concept was approved by
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medizin Berlin.
Relaxation intervention
To induce a relaxation response, 3 exercises (AT, mind-
fulness meditation and guided imagery) with a length of
15 minutes each will be made available in 2 versions
(female and male voice). They will be accompanied by a
short instructional text. Relaxation exercises can be ap-
plied in different positions (sitting, walking and lying),
which can be chosen by the participants according to
their needs. The relaxation exercise should be applied
daily or at least 5 days per week for 6 months.
AT was developed by the German psychiatrist Johannes
Schultz in 1932. The AT audio has a focus on the physical
sensation of the breath or heartbeat and visualizes the
body as warm, heavy and/or relaxed [44]. The AT teaches
participants to react to six verbal commands such as ‘my
arms are very heavy’, ‘my heart beats regularly and calm’
and ‘my belly is warm’ to make the body feel relaxed.
Mindfulness is a practice rooted in Vipassana (transla-
tion: insight) meditation, which has Buddhist roots. It is de-
fined as ‘paying attention in a particular way: on purpose,
in the present moment and in a nonjudgmental way’ [45].
The mindfulness meditation focuses on the breath and uses
the breath as an anchor when the mind starts to wander.
This concept is also used in Mindfulness-Based Stress
Reduction developed by Kabat-Zinn [45-47].
In guided imagery, the mind is directed to intentionally
create images to produce positive changes [48]. The audio
guides participants to visualize/conjure a place that is asso-
ciated with positive feelings such as safety, security and
well-being. The guided imagery audio is accompanied
by soft background music and directs the visualization
and imagination to a pleasant and peaceful place that
has meaning for the participant to replace negative or
stressful feelings [49].
Control group
Patients in the control group continue using usual care
defined as all medical and non-medical treatments; how-
ever, relaxation techniques, mindfulness meditation or
any other mindfulness-based training are not permitted.
Outcome measurement
The primary outcome measure will be the mean LBP or
NP intensity during the first 3 months of intervention
based on daily pain intensity measurements on a NRS
(0 = no pain, 10 = worst possible pain) [50].
The secondary outcome parameters include the fol-
lowing: the mean pain intensity during the first 6 months
after randomization based on daily measurements; the
mean pain intensity (NRS) measured weekly as the aver-
age pain intensity of the previous 7 days over 3 and6 months; pain acceptance (German version of Chronic
Pain Acceptance Questionnaire [51]); ‘LBP-/NP-related
stress’; sick leave days; and pain medication intake.
Additionally, we will collect data about expectations,
adherence, self-reported general changes in LBP/NP,
suspected adverse reactions and serious adverse events.
The outcome measures including the time points are
listed in Table 1.
Data collection
Baseline information will be collected using paper and
pencil, and all follow-up data will be collected using the
study app.
The study app features electronic daily and weekly
diaries in which study participants will log daily data re-
garding their LBP/NP intensity and weekly data on
medication intake, average pain intensity over the previ-
ous 7 days based on a NRS (‘How strong was your mean
pain intensity in the last 7 days?’), and ‘LBP-/NP-related
stress’. Daily and weekly data will be collected through-
out the 6-month period. Furthermore, the apps include
questionnaires that appear after the end of the third and
sixth months.
Assessment of adherence
Adherence will be assessed by 1) tracking of the running
time of the relaxation audios (start and end times, and
the type of relaxation) and 2) by asking the participants
how much time they spent doing the relaxation exercises
without using the app.
Assessment of safety
Adverse events and suspected adverse reactions (only
in the intervention group) are assessed after the third
and sixth months using the questionnaire provided by
the app.
Sample size
In the literature, an effect size of 0.62 has been described
for mind-body therapies compared to no intervention in
a group setting [29]. We assume a smaller effect size of
0.4 (Cohen’s d, baseline adjusted) for individual self-care
relaxation exercise compared to usual care alone be-
cause individuals might be less focused and consequently
less adherent in a self-care setting. To obtain a power of
80% using a 2-sided t-test with significance level of 0.05,
100 participants for each treatment group are needed (a
total of 200 participants). We will include 110 partici-
pants per group (220 in total for each study) to compen-
sate for dropouts.
Data analyses
For each study, the primary analysis of the primary out-
come (mean pain intensity over 3 months measured as
Table 1 Data collection: except for the baseline data, outcomes are assessed throughout the 6-month period
Baseline Dailyd Weeklyd After third monthd After sixth monthd
Socio-demographics (age, migration background, education) x
Pain intensity (NRS) x
Mean pain intensity in the last 7 days (NRS) x x
Mean perceived ‘LBP-/NP-related’ stress intensity in the last 7 days (NRS) x x
Pain acceptance x x x
Sick leave days x x x
Intake of medication against LBP/NP x x
Suspected adverse reactiona x x
Serious adverse events x x
Application of other therapies x x x
Expectation x
Adherencea xb xc
Self-perceived improvement xa xa
aOnly in the intervention group.
bAssessed by tracking.
cAssessed by the diary (for relaxation without audio use).
dProvided by the app.
Abbreviations: LBP, low back pain; NP, neck pain; NRS, numeric rating scale.
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using an analysis of covariance (ANCOVA) with a fixed
factor of ‘treatment group’, adjusted for the baseline
NRS value (fixed covariate). This will be used to test the
null hypothesis of equal mean pain intensity between the
two treatment groups. The analysis will be based on the
full analysis set (FAS, all available data without imput-
ation of missing values, based on the intention-to-treat
principle) with a 2-sided significance level of 0.05. The
results will be reported as adjusted group means with
95% confidence intervals and the P-value for the group
comparison. All further analyses on the primary and all
secondary outcomes will be considered explorative, and
no adjustment for multiple testing will be performed.
The secondary outcomes will be analyzed for the FAS
similarly to the primary analysis depending on the scale
and distribution of the data, that is ANCOVA, logistic
regression, or Poisson regression, adjusted for the re-
spective baseline value (when available). For the sensitiv-
ity analysis, the primary analysis of the primary outcome
will be repeated based on the per-protocol population.
In addition, missing data on the primary outcome will
be imputed using multiple imputation techniques or
other methods depending on the assumed missing data
mechanism(s). In case of relevant differences in baseline
variables between the treatment groups, the analysis of
the primary outcome will be repeated with additional
adjustment for these variables. As further supportive
analysis, a mixed model for repeated measures (MMRM)
will be fitted to compare the two treatment groups with
respect to changes in the primary outcome over time.
The model will include terms for treatment and time asfixed main effects, an interaction term for treatment by
time, and the subject as a random effect, adjusted for
the baseline value. The following subgroups will be con-
sidered for exploratory analyses: age groups, education
(>10 years of school education, ≤10 years of school edu-
cation), sex (male/female), severity of disease and dur-
ation of disease. Subgroup analyses will be performed on
the primary outcome by including an interaction term
(subgroup variable by treatment) in the main model, as
well as by performing separate analyses for each sub-
group. A detailed statistical analysis plan (SAP) will be
developed prior to any data analyses. Data analysis will
be performed in SAS version 9.3 or higher (SAS Inc.,
Cary, NC, USA).
Ethics
The protocols of the studies were approved by the local
ethics review boards at the Charité - Universitätsmedizin
Berlin (approval number: Relaxback EA 1/260/13 and
Relaxneck EA 1/259/13), and the studies will be con-
ducted according to common standard guidelines for
clinical trials (Declaration of Helsinki, and where it ap-
plies, the International Conference on Harmonization of
Technical Requirements for Registration of Pharmaceu-
ticals for Human Use and Good Clinical Practice (ICH-
GCP) revised version, Somerset West, Republic of South
Africa, 1996). All study participants will provide oral and
written informed consent.
Pragmatic explanatory continuum summary
From a methodological point of view, a study can be
more focused on effectiveness or efficacy. ‘Effectiveness’
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vention, when deployed in the field in routine circum-
stances, does what it is intended to do for a specific
population, whereas ‘efficacy’ refers to the extent to which a
specific intervention is beneficial under ideal conditions
[52]. The assessment of effectiveness in pragmatic trials can
often be more relevant to policy evaluation and the health
care decisions of providers and patients than the assess-
ment of efficacy in explanatory trials [53]. Therefore,
greater detail and transparency in reporting of the interven-
tion characteristics, settings and assessment specifics are
needed [54,55]. The pragmatic explanatory continuum
summary (PRECIS) [56] was developed to provide a graph-
ical tool of ten design domains, which helps researchers
categorize a trial’s focus as more pragmatic (effectiveness)
or explanatory (efficacy). However, clinical studies are very
often placed somewhere in the middle of the pragmatic-
explanatory continuum [53,57].
Three of the authors (CMW, DP, SB) determined the
placement of the study using PRECIS. The place of our
trial in the pragmatic-explanatory continuum was de-
fined more on the pragmatic side for the criteria of pri-
mary analysis, relaxation protocol, control protocol,
eligibility criteria and outcome measurements, whereas
participant compliance, follow-up intensity, and relax-
ation protocol were more on the explanatory side
(Figure 1). Based on the ten PRECIS criteria, practitioner
expertise and adherence were not applicable, so that 8
study design criteria remained.
Discussion
To the best of our knowledge, these are the first ran-
domized pragmatic trials that will investigate whetherFigure 1 Pragmatic-explanatory continuum indicator summary (PRECIS)
criteria to be more on the pragmatic side (outer circles), more of the expapp-delivered relaxations are an effective method to re-
duce chronic LBP or NP.
Chronic LBP and NP are common problems that con-
stitute a large socioeconomic burden [4,7,58], and self-
care therapies delivered by an App are easy to apply in a
‘real world setting’. Despite an increasing number of
available pain related apps, very few of them have been
tested for effectiveness [41]. Therefore, we planned both
studies as pragmatic trials.
Due to the similar disease pattern of the two condi-
tions, the intervention and study design is suitable for
both patient groups, thus fewer resources than usual
were necessary to conduct two parallel trials.
The involvement of relevant stakeholders contributed
positively to the development process of the two study
protocols. One important result of the stakeholder in-
volvement was the reduction of the exercise duration
from 20 to 15 minutes daily because the stakeholders
suggested that long exercise time might be associated
with difficulty following the recommended protocol:
15 minutes was considered the minimal daily exercise
time that is necessary to achieve a treatment effect, espe-
cially outside of a group setting, and this length was
chosen to improve patient adherence to the exercises.
Adherence is a strong predictor of treatment success in
patients with chronic LBP [59]. To support adherence,
we implemented notifications in the app that can be
individualized and remind the participants to perform
the exercises. The selection of three different exercises
to induce the relaxation response considers the indi-
vidual’s expectations, beliefs and preferences [60] and
contributes to a more personalized, patient-centered
therapy.for the main study displaying the location of the eight study design
lanatory side (inner circles), or in the middle of the continuum.
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data collection. The content and the length of the elec-
tronic questionnaires and the diaries were chosen based
on our previous experience with an app as a data collec-
tion tool in a study on menstrual pain [57]. Broad stake-
holder involvement revealed that outcome measurements
should be patient-relevant. It also indicated that app-
delivered questionnaires can be provided more frequently
than paper-pencil questionnaires as the completion of the
questionnaires on smartphones requires less time [57].
Consequently, the app includes one daily question, short
weekly diaries and two longer questionnaires only after
the third and the sixth months. However, although we
tried to minimize the number of outcome measurements,
the valid tool for assessing pain acceptance [51] (after the
third and sixth month) includes 20 questions and had to
be implemented. Moreover, questionnaires adapted for
app delivery are not yet validated and no data exists on
whether the length or the frequency of electronic ques-
tionnaires influences the drop-out rates in randomized
controlled trials.
We decided to measure pain intensity (NRS) daily and
the average pain intensity over the previous 7 days was
used to investigate whether there are differences be-
tween these 2 methods of pain assessment. This ap-
proach takes into account the consistent findings in pain
assessment research that have shown that recall ratings
of average pain might overestimate pain compared to
‘actual’ pain scores received from daily diaries [61-64],
and it might minimize recall bias. Hence, the results of
the study will add evidence to the ongoing discussion of
the potential utility of recall ratings in pain clinical trials.
The main limitation of the study is that the patients
will not be blinded, which might increase bias. It has
been reported that bias due to lack of patient blinding is
pronounced in complementary/alternative randomized
clinical trials with patient-reported outcomes. However,
the designed studies reflect a usual self-care setting and
will provide evidence for a pragmatic self-care interven-
tion that is easy to combine with care provided by med-
ical professionals.Trial status
Recruitment was started in March 2014.
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